RxDoctor Payments Data

Toni Wilcher

Adult Health · Indianapolis, INNPI 1104131515

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Novo Nordisk at 33.6% of the total.

$3,260in general payments, 2019–2025

Across 81 payments — averaging $40.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Biohaven Pharmaceuticals, Inc.$399
  • Lilly USA, LLC$337
  • AbbVie$332
  • AstraZeneca$268
  • Exact Sciences$183
  • plus $646 from 14 others

What the payments were for

  • Food & beverage$3,260100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,260 in reported general payments places this provider in the 85th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$34,795
Medicare patients
223
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$33,577
JardianceEmpagliflozin21$22,731
LinzessLinaclotide12$13,975
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,127
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,960
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$1,276
Albuterol Sulfate HfaAlbuterol Sulfate65$871
Fluticasone Propionate46$765
Omeprazole45$677
Atorvastatin Calcium77$615
Doxycycline Hyclate66$526
Duloxetine Hcl17$512
Pantoprazole Sodium42$494
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav50$475
Amlodipine Besylate56$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,094$33,57718 claims
Boehringer IngelheimJardiance$32$22,73121 claims
AbbVieLinzess$332$13,97512 claims
GSKTrelegy Ellipta$15$12,12715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 391 adult health providers in Indiana.

Other adult health in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →